1. Psoriasis

Category Archives: Psoriasis

Amgen-AstraZeneca Psoriasis Drug Scores – Analyst Blog

Posted on by

Amgen ( AMGN ) and partner, AstraZeneca ( AZN ), presented positive phase III data on their experimental psoriasis treatment, brodalumab. The candidate was evaluated in a phase III study, AMAGINE-1, in patients with moderate-to-severe plaque psoriasis.

Amgen and AstraZeneca said that the primary as well as secondary endpoints were achieved. Two doses of brodalumab (140 mg and 210 mg) were compared to placebo. While 83.3% of patients in the 210 mg group and 60.3% of patients in the 140 mg group achieved PASI 75 responses, only 2.7% of patients in the placebo arm achieved the same.

As far as PASI 90 response was concerned, 70.3% and 42.5% of patients in the 210 mg and 140 mg arms, respectively, achieved the same compared to 0.9% in the placebo arm. PASI 100 responses were achieved by 41.9% and 23.3% patients in the 210 mg and 140 mg arms, respectively, compared to just 0.5% in the placebo arm.

The PASI score basically measures psoriatic plaque redness, scaling and thickness and the extent of involvement in each region of the body.

Our Take

The phase III data on brodalumab is encouraging for both Amgen and AstraZeneca. These results bring Amgen and AstraZeneca a step closer to regulatory filing though two more phase III studies are still ongoing - AMAGINE-2 and AMAGINE-3. Results from these two head-to-head studies comparing brodalumab to Stelara (ustekinumab) should be out later this year. Both companies are working on strengthening their product portfolio and brodalumab is one of the key candidates in their pipeline. According to a recent press release issued by AstraZeneca, analyst estimates for brodalumab range between $0.5 billion - $1.5 billion.

However, the psoriasis market is highly crowded with treatments like Stelara and Otezla among others. Moreover, several companies have late-stage candidates in development for the psoriasis market.

Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks. Some better-ranked stocks in the health care sector include Gilead Sciences ( GILD ) and Allergan ( AGN ). While Gilead is a Zacks Rank #1 (Strong Buy) stock, Allergan is a Zacks Rank #2 (Buy) stock.

ALLERGAN INC (AGN): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

Read more:

Amgen-AstraZeneca Psoriasis Drug Scores - Analyst Blog

Amgen-AstraZeneca Experimental Medicine Eases Psoriasis

Posted on by

Amgen Inc. (AMGN) and AstraZeneca Plc (AZN)s experimental drug brodalumab eased symptoms of psoriasis at both doses tested in a key study needed for U.S. approval.

The medicine for moderate to severe plaque psoriasis dispersed the thick red patchy scales on patients skin, leaving it markedly clearer than those getting a placebo, the companies said today in a statement. The study is the first from the final round of tests on the drug. Two studies comparing it with Johnson & Johnsons Stelara are expected by year end, said Sean Harper, executive vice president of research and development for Amgen, the worlds biggest biotechnology company by revenue.

The psoriasis drug is part of a 2012 collaboration between Thousand Oaks, California-based Amgen and London-based AstraZeneca to develop five medicines from Amgens portfolio of therapies for inflammation. AstraZeneca is currently grappling with a $106 billion acquisition bid from Pfizer Inc., which executives rejected last week as too low because it undervalued the U.K. companys drug pipeline.

Brodalumab works in a different manner than existing drugs and rivals in development, latching on to the interleukin 17 receptor and blocking inflammation thats a key driver of the disease. Novartis AG and Eli Lilly & Co. are also working on medicines to treat psoriasis, which would compete with drugs including J&Js Stelara and Amgens Enbrel.

The study of 661 patients found 83 percent in the high-dose brodalumab arm and 60 percent getting a lower dose had the severity of their disease lessen by at least 75 percent after three months of treatment, compared with a similar benefit in 2.7 percent of patients given a placebo.

About 125 million people worldwide suffer from the skin condition, including about 7.5 million Americans, according to the National Psoriasis Foundation.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Andrew Pollack, Angela Zimm

View post:

Amgen-AstraZeneca Experimental Medicine Eases Psoriasis

Amgen, AstraZeneca Say Ph 3 Study Of Psoriasis Drug Brodalumab Meets Goals

Posted on by

By RTT News, May 09, 2014, 04:18:00 PM EDT

(RTTNews.com) - Amgen Inc. ( AMGN ) and AstraZeneca PLC (AZN, AZN.L) said Friday that the Phase 3 AMAGINE-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.

Brodalumab is the only investigational treatment in development that binds to the interleukin-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor.

Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index, and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment.

Psoriasis is a non-contagious chronic disease in which the immune system causes skin cells to grow at an accelerated rate. Instead of being shed, skin cells pile up, causing painful and itchy, red, scaly patches.

AMAGINE-1 is one of three Phase 3 studies designed to assess the efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis. AMAGINE-2 and AMAGINE-3 are designed to evaluate the efficacy and safety of induction and maintenance regimens of brodalumab at different dose schedules in patients with moderate-to-severe plaque psoriasis compared to ustekinumab and placebo.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Go here to see the original:

Amgen, AstraZeneca Say Ph 3 Study Of Psoriasis Drug Brodalumab Meets Goals

Atopic (Eczema) Dermatitis, Seborrheic Dermatitis, Psoriasis with/without Hair Loss – Video

Posted on by


Atopic (Eczema) Dermatitis, Seborrheic Dermatitis, Psoriasis with/without Hair Loss
Controls symptoms of: Seborrheic Dermatitis, Psoriasis, Minor Severe Dandruff, Relief of scalp skin itching, irritation flaking associated with Atopic Dermatitis.

By: ALBRA DEWYN LLC

Read the original here:

Atopic (Eczema) Dermatitis, Seborrheic Dermatitis, Psoriasis with/without Hair Loss - Video

Aggravation of Psoriasis after stopping Methotrexate, patient shares his experience – Video

Posted on by


Aggravation of Psoriasis after stopping Methotrexate, patient shares his experience
A video of patient who was suffering with Psoriasis was prescribed methotrexate for his ailment. When he was on methotrexate conditions were in control, once...

By: lifeforcehomeopathy

Here is the original post:

Aggravation of Psoriasis after stopping Methotrexate, patient shares his experience - Video

Skin rash patients hardest hit by ban on beach nudity at Sanya

Posted on by

China's beach resort city, Sanya, is strengthening its ban on nude sunbathing and swimming on public beaches this month, but experts are calling for patients with psoriasis treating their diseases with sun to have their space.

Starting on Sunday, Sanya police took several measures to beef up the ban: increasing patrols on public beaches, passing out fliers to discourage people from naked sunbathing, and taking pictures of violators. High-definition surveillance cameras are also being installed.

Since Feb 8, nude sunbathing and swimming at public beaches has been forbidden. Violators will be detained for five to 10 days. So far, two people have been detained since the ban was imposed.

But, Zhou Xiaozheng, a sociologist at Renmin University of China who researches outdoor recreation in the country, said most nude sunbathers in Sanya are psoriasis patients.

"These people are not intentionally exposing their private parts. They need sunshine for medical treatment," Zhou said.

Shen Hong, a dermatologist at Hangzhou No 3 People's Hospital, said psoriasis is a chronic skin disease that is difficult to cure.

"For patients with psoriasis, red patches with scales will occur, especially on their scalp, ears and genitalia. Abundant sunshine and washing with seawater can relieve the pain caused by these patches," he said.

Sanya Mayor Wang Yong conceded that psoriasis patients are among the nude beachgoers in the city.

"There were dozens of patients with such skin disease when nude sunbathing started to appear in Sanya in 2002," he said. "They had notices from doctors, suggesting that they sunbathe for a certain amount of time. But we do not think this should take place in the city, especially when the group of patients has grown to the hundreds."

Wang said nude swimming and sunbathing is uncivilized behaviour and may disturb other beachgoers.

Here is the original post:

Skin rash patients hardest hit by ban on beach nudity at Sanya

Tampa dermatologist emerges as regional expert for psoriasis, hidradenitis

Posted on by

With word spreading about Carrollwood based Forman Dermatologys expertise in skin care needs, especially psoriasis and hidradenitis suppurativa, the Tampa area clinic is beginning to see an increase in patients from around the region.

It truly is a thrill when talking to patients who say they have traveled as long as two or three hours for treatment, says Tampa Dermatologist Dr. Seth Forman. It is a testament to the staff that people are passing other dermatologists to instill their trust in us.

Coming as far as Orlando, Ocala and Naples, patients have sought out Forman Dermatology due to the clinics expertise in the treatment of chronic conditions like psoriasis and hidradenitis suppurativa.

Dr. Formans treatment includes the state-of-the-art Psoria-Light, as well as the SRT-100, a groundbreaking nonsurgical radiotherapy treating basal cell carcinoma.

As one of the select few given the ability to host drug trials at his office, the Tampa dermatologist offers other innovative treatments for skin cancer, psoriasis and vitiligo.

Rounding out the full-service dermatology practices toolkit is the high-quality cosmetic as well as medical spa services offered, helping the Forman Dermatology and Skin Cancer Institute become a top dermatology office in not just Tampa, but the entire Tampa Bay and Central Florida communities.

Thanks to the advance technology in our office, weve been able to help so many more people, says the Tampa dermatologist.

For more on Dr. Seth Forman, Tampa dermatology or Forman Dermatology and Skin Cancer Institute, please visit http://www.FormanDerm.com.

About Dr. Seth Forman:Dr. Forman is a board-certified dermatologist practicing in Tampa, Florida. He was voted the Best Dermatologist in Carrollwood in 2011, 2012 and 2013 by the Carrollwood News and Tribune as well as the 2013 Best Dermatologist in North Tampa by the Tampa Tribune. In December 2011, he opened his new Tampa dermatologyoffice, Forman Dermatology and Skin Cancer Institute, where he gives psoriasis sufferers access to the latest treatment options, including topical and oral medications, as well as biological and phototherapy. Dr. Forman is one of the few Tampa dermatologists to offer narrowband light therapy, which uses pharmaceutical grade light to suppress psoriasis. Hes also one of the few board-certified dermatologists in the U.S. to use the SRT-100 radiotherapy to treat basal cell carcinoma, the most common form of skin cancer.

MEDIA CONTACT Nathan Legg PR Firm: The Publicity Agency Email: Nathan@Seligmultimedia.com Phone: (813) 708-1220 x 7781 Website: http://www.thepublicityagency.com

See the original post here:

Tampa dermatologist emerges as regional expert for psoriasis, hidradenitis


  1. Psoriasis